Jiangsu Hengrui Pharmaceuticals Co. Ltd. (JHPCY)

Profile

https://www.hengrui.com

Jiangsu Hengrui Pharmaceuticals Co. Ltd. is a leading biopharmaceutical company engaged in the research, development, manufacture, and commercialization of innovative drugs primarily in China and internationally. It specializes in antineoplastic agents for cancer treatment, surgical anesthesia drugs, infusion solutions, contrast agents, cardiovascular medications, endocrine therapies, anti-infection drugs, and products for autoimmune diseases, pain management, metabolic disorders, respiratory conditions, hematological diseases, neurological issues, and ophthalmology. The company's diverse portfolio encompasses tablets, oral solutions, suspensions, soft capsules, freeze-dried powder injections, high-volume and small-volume injections including multi-layer co-extruded infusion bags, biological engineering products like polyethylene glycol recombinant human granulocyte stimulating factor injections, hard capsules, granules, powders, films, and gels. Jiangsu Hengrui Pharmaceuticals Co. Ltd. also provides technical consulting, training, investment advisory, technology development, and import-export services for pharmaceuticals. Founded in 1970 and headquartered in Lianyungang, China, it plays a significant role in the global healthcare sector, focusing on high-quality, specialized therapeutics across multiple therapeutic areas.